Cholestatic Drug-Induced Liver Injury in a Patient Taking High-Dose Niacin for Hyperlipidemia.
J Investig Med High Impact Case Rep
; 12: 23247096231224349, 2024.
Article
en En
| MEDLINE
| ID: mdl-38193433
ABSTRACT
Niacin, an important component of a balanced diet, is central to lipid metabolism. Occasionally used to treat hyperlipidemia, niacin is widely available without a prescription, making its use often unknown to treating physicians. Severe hepatotoxicity has been reported with niacin use. In the following report, we describe a case of hospitalization for acute decompensated cirrhosis with cholestatic morphology in a patient taking self-initiated large quantities of extended-release niacin. Despite medical management and support, the patient unfortunately expired on day 16 of hospitalization. Given ease of access and unclear long-term benefit in hyperlipidemia, the current case serves to raise awareness of niacin's potential hepatotoxicity through highlighting a severe outcome. Although mode of liver injury remains unknown, the use of extended-release niacin formulations and prolonged high-dose supplementation is associated with enhanced hepatotoxicity. Careful review and counseling of commonly available supplements remains an important task of both hospital and primary care physicians.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Colestasis
/
Enfermedad Hepática Inducida por Sustancias y Drogas
/
Hiperlipidemias
/
Niacina
Tipo de estudio:
Etiology_studies
Límite:
Humans
Idioma:
En
Revista:
J Investig Med High Impact Case Rep
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos